This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
by Zacks Equity Research
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zai Lab Limited (ZLAB) Surges 9.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zai Lab Limited (ZLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why 'Trend' Investors Would Love Betting on Zai Lab Limited (ZLAB)
by Zacks Equity Research
Zai Lab Limited (ZLAB) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Believe Zai Lab Limited (ZLAB) Could Rally 95.6%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
by Zacks Equity Research
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zai Lab Limited (ZLAB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Compared to Estimates, Zai Lab Limited (ZLAB) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Best Momentum Stocks to Buy for July 10th
by Zacks Equity Research
KGC, ZLAB, and EAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 10, 2024.
New Strong Buy Stocks for July 10th
by Zacks Equity Research
AY, APOG, KGC, ZLAB, and FNKO have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2024.
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
by Zacks Equity Research
Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
by Zacks Equity Research
Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.
Zai Lab (ZLAB) Up on Breakthrough Therapy Tag for Oncology Drug
by Zacks Equity Research
Zai Lab (ZLAB) gains on receiving Breakthrough Therapy designation for repotrectinib from the Center for Drug Evaluation of the National Medical Products Administration in China.
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?
by Zacks Equity Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seagen's (SGEN) Q1 Earnings and Revenues Miss Expectations
by Zacks Equity Research
Seagen (SGEN) reports worse-than-expected results in the first quarter of 2023, missing both earnings and sales estimates.
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Does Zai Lab Limited Unsponsored ADR (ZLAB) Have the Potential to Rally 115.25% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 115.3% upside potential for Zai Lab Limited Unsponsored ADR (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.